Evaluating the Therapeutic Efficacy of an Anti-BAFF Receptor Antibody Using a Rheumatoid Arthritis Mouse Model

Area of Science:

• Immunology
• Rheumatology
• Drug Discovery

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting 0.5-1% of the global population, causing joint inflammation, tissue damage, and disability.
• Current treatments like DMARDs and B-cell-targeting therapies have limitations, including broad immunosuppression and increased infection risk.
• There is a need for selective therapies that modulate pathogenic immune pathways while preserving protective immunity, with BAFF pathway targeting proposed as a favorable approach.

Purpose of the Study:

• To evaluate the therapeutic potential of V3-46s mIgG2a, an anti-BAFF-R (BR3) antibody.
• To test the hypothesis that targeting BAFF-R offers a more selective and effective strategy for rheumatoid arthritis treatment.

Main Methods:

• Four antibody variants were expressed and purified, with binding and neutralizing activity assessed in vitro.
• The selected antibody, V3-46s mIgG2a, was evaluated in vivo using a collagen-induced arthritis (CIA) mouse model.

Main Results:

• Treatment with V3-46s mIgG2a delayed the onset of arthritis in the CIA model.
• The antibody treatment reduced overall arthritis severity, spleen index, and B-cell populations.

Conclusions:

• BAFF-R-targeting antibodies demonstrate potential as a therapeutic strategy for rheumatoid arthritis.
• This preclinical research supports BAFF-R blockade as a potential complementary or alternative treatment to existing biologic therapies for RA.